Previous 10 | Next 10 |
– Data Support the Ongoing Phase 3 STAR-221 Study of Domvanalimab Plus Zimberelimab and Chemotherapy, Potentially the First Anti-TIGIT Combination to Market for These Cancers – – Results will be Presented Today During an Oral Session at the ASCO Annual Meeting ...
2024-05-26 08:05:48 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...
2024-05-24 15:00:53 ET More on the markets S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight SPY ETF: Momentum Is In The Cards Stocks have more room to run - Invesco's Kristina Hooper Big bear Mike Wilson changes tune a...
2024-05-15 03:38:24 ET Summary Arcus Biosciences is preparing for a readout at the ASCO Annual Meeting, which could be a significant catalyst for the company. The company has a strong financial position with $1.1 billion in current assets, but has a quarterly loss of $4 million. ...
2024-05-13 07:58:54 ET Merck ( NYSE: MRK ) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial .... Read the full article on Seeking Alpha For further details see: Merck discontinues testing of experimental skin...
2024-05-08 21:55:26 ET Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Pia Eaves - Vice President of Investor Relations & Strategy Terry Rosen - CEO Jennifer Jarrett - COO Bob Goeltz - CFO Di...
2024-05-08 16:36:18 ET More on Arcus Biosciences Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Arcus Biosciences Historical earni...
Arcus data will be disclosed in two oral presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Updated data, including median progression-free survival (PFS), from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper GI cancers ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...